Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker AVIR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi | 9.08M | 11.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | JPM Partners LLC | 5.12M | 6.4% | SCHEDULE 13G/A ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Tang Capital Partners III, Inc | 661,104 | 0.8% | SCHEDULE 13G ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Tang Capital Partners International, LP | 1.67M | 2.1% | SCHEDULE 13G ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Tang Capital Partners, LP | 2.49M | 3.1% | SCHEDULE 13G ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Kevin Tang | 4.81M | 6.0% | SCHEDULE 13G ↗ |
| Oct 6, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Tang Capital Management, LLC | 4.81M | 6.0% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Abigail P. Johnson | 11.95M | 15.0% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | FMR LLC | 11.95M | 15.0% | SCHEDULE 13G/A ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 9, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | Leonard Braden Michael | 7.81M | 9.9% | SCHEDULE 13G ↗ |
| Feb 9, 2026 | SCHEDULE 13G | AVIR Atea Pharmaceuticals, Inc. | BML Investment Partners, L.P. | 7.49M | 9.6% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Abigail P. Johnson | 9.10M | 11.6% | SCHEDULE 13G/A ↗ |
| Dec 5, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | FMR LLC | 9.10M | 11.6% | SCHEDULE 13G/A ↗ |
| Aug 6, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Abigail P. Johnson | 5.72M | 6.7% | SCHEDULE 13G/A ↗ |
| Aug 6, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | FMR LLC | 5.72M | 6.7% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi | 8.88M | 10.1% | SCHEDULE 13G/A ↗ |
| May 14, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | JPM Partners LLC | 5.87M | 6.9% | SCHEDULE 13G/A ↗ |
| Apr 23, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | BlackRock, Inc. | 6.08M | 7.1% | SCHEDULE 13G/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | James P. Flynn | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Nerium Capital LLC | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Nerium Partners LP | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Howard H. Berman | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Michael Torok | 1.50M | 1.8% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Mos PTC, LLC | 100,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | The MOS Trust | 100,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | JEC II Associates, LLC | 1.30M | 1.5% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Bradley Louis Radoff | 3.38M | 4.0% | SCHEDULE 13D/A ↗ |
| Apr 17, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Radoff Family Foundation | 185,000 | 0.2% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | James P. Flynn | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Nerium Capital LLC | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Nerium Partners LP | 54,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Howard H. Berman | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Michael Torok | 1.50M | 1.8% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Mos PTC, LLC | 100,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | The MOS Trust | 100,000 | 0.1% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | JEC II Associates, LLC | 1.30M | 1.5% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Bradley Louis Radoff | 3.11M | 3.6% | SCHEDULE 13D/A ↗ |
| Mar 21, 2025 | SCHEDULE 13D/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Radoff Family Foundation | 175,000 | 0.2% | SCHEDULE 13D/A ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | Michael Torok | 1.50M | 1.8% | SCHEDULE 13D ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | Mos PTC, LLC | 100,000 | 0.1% | SCHEDULE 13D ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | The MOS Trust | 100,000 | 0.1% | SCHEDULE 13D ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | JEC II Associates, LLC | 1.30M | 1.5% | SCHEDULE 13D ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | Bradley Louis Radoff | 2.82M | 3.3% | SCHEDULE 13D ↗ |
| Mar 4, 2025 | SCHEDULE 13D | AVIR Atea Pharmaceuticals, Inc. | Radoff Family Foundation | 165,000 | 0.2% | SCHEDULE 13D ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | EcoR1 Capital Fund Qualified, L.P. | 3.16M | 3.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | Oleg Nodelman | 3.34M | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | AVIR Atea Pharmaceuticals, Inc. | EcoR1 Capital, LLC | 3.34M | 4.0% | SCHEDULE 13G/A ↗ |
49 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances